0000000000042519

AUTHOR

Gunnar H. Heine

showing 4 related works from this author

CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-α levels

2004

SummaryMonocytes play a central role in the inflammatory disease atherosclerosis. CD14+CD16+ monocytes are considered proinflammatory monocytes, as they have an increased capacity to produce proinflammatory cytokines, such as TNF-α, and are elevated in various inflammatory diseases. We hypothesized that patients with coronary artery disease (CAD) have increased levels of CD14+CD16+ monocytes, and that CD14+CD16+ monocytes are associated with inflammation markers. We investigated CD14+CD16+ monocytes in 247 patients with CAD and 61 control subjects using flow cytometry. In addition serum concentrations of TNF-α, IL-6, and Hs-CRP were assessed. Patients with CAD had higher levels of CD14+CD16…

MaleArteriosclerosismedicine.medical_treatmentCD14Lipopolysaccharide ReceptorsInflammationCell SeparationCoronary Artery DiseaseCD16MonocytesBody Mass IndexProinflammatory cytokineCoronary artery diseaseRisk FactorsOdds RatioHumansMedicineAgedInflammationAnalysis of VarianceInterleukin-6Tumor Necrosis Factor-alphabusiness.industryMonocyteReceptors IgGAntibodies MonoclonalHematologyMiddle AgedFlow Cytometrymedicine.diseaseLogistic ModelsCytokinemedicine.anatomical_structureCase-Control StudiesImmunologyFemaleTumor necrosis factor alphamedicine.symptombusinessThrombosis and Haemostasis
researchProduct

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

2008

Background Patients with chronic kidney disease (CKD) have an increased risk for cardiovascular events (CVE). Uraemic dyslipidaemia, which is characterized by low HDL-cholesterol (HDL-C) and elevated triglycerides' levels, may contribute to this elevated cardiovascular risk. Cholesteryl ester transfer protein (CETP) lowers HDL-C by transferring cholesterol esters to LDL and VLDL particles. We tested the hypothesis that CETP activity is associated with CVE in patients with CKD stage V. Methods We measured CETP activity and cholesterol levels in 69 haemodialysis patients. CVE and death were prospectively assessed over a follow-up period of 48 months. Results CETP activity was negatively corre…

MaleVery low-density lipoproteinmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionKaplan-Meier EstimateSeverity of Illness IndexCohort Studieschemistry.chemical_compoundPredictive Value of TestsRisk FactorsInternal medicineCholesterylester transfer proteinmedicineHumansMyocardial infarctionProspective StudiesAngioplasty Balloon CoronaryCoronary Artery BypassProspective cohort studyStrokeAgedAged 80 and overTransplantationbiologybusiness.industryCholesterolCholesterol HDLMiddle Agedmedicine.diseaseCholesterol Ester Transfer Proteinscarbohydrates (lipids)StrokeEndocrinologychemistryNephrologyChronic Diseasebiology.proteinlipids (amino acids peptides and proteins)FemaleKidney DiseasesStentsHemodialysisbusinessBiomarkersKidney diseaseFollow-Up StudiesNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

CKD NUTRITION, INFLAMMATION AND OXIDATIVE STRESS

2014

Introduction and Aims: Serum p-cresyl sulfate associates with cardiovascular disease in patients at different stages of chronic kidney disease. p-Cresyl sulfate concentrations are determined by intestinal uptake of p-cresol, human metabolism to p-cresyl sulfate and renal clearance. Whether intestinal uptake of p-cresol itself is associated with cardiovascular disease in patients with renal disease has not been studied to date. Methods: We performed a prospective study in patients with chronic kidney disease stage 1-5 (clinicaltrials.gov NCT00441623). Intestinal uptake of p-cresol, under steady state conditions, was estimated from 24h urinary excretion of p-cresyl sulfate. Primary endpoint w…

Transplantationmedicine.medical_specialtyFramingham Risk ScoreCardiovascular Historybusiness.industryHazard ratioRenal functionmedicine.diseaseGastroenterologyEndocrinologyNephrologyDiabetes mellitusInternal medicinemedicineMyocardial infarctionProspective cohort studybusinessKidney diseaseNephrology Dialysis Transplantation
researchProduct

PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study.

2009

Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 p…

Malemedicine.medical_specialtyMyocardial InfarctionQD415-436Coronary Artery DiseaseKaplan-Meier Estimatelipid transfer proteinsBiochemistryCoronary artery diseasechemistry.chemical_compoundEndocrinologyRisk FactorsInternal medicinePhospholipid transfer proteinmedicineHumansMyocardial infarctionRisk factorPhospholipid Transfer Proteins3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorsAgedCholesterolbusiness.industryProportional hazards modelConfoundingCase-control studyCell BiologyMiddle Agedmedicine.diseaseAtherosclerosisPrognosisEndocrinologychemistryCase-Control StudiesCardiologyFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPatient-Oriented and Epidemiological ResearchFollow-Up StudiesJournal of lipid research
researchProduct